Trials in Progress Abstract Submission Guidelines

Trials in Progress abstract submissions provide a unique opportunity for members of the research community to present ongoing trials and discuss corollaries and novel trial designs with colleagues. Submitters should use the Clinical Trials category for their Trials in Progress abstracts.

Any phase (I, II, or III) trial that is ongoing and has not yet reached prespecified endpoints for analysis may be considered for inclusion in Trials in Progress submissions. As such, inclusion of results would be improper and is strictly forbidden.

All submissions will be reviewed for appropriateness by the Scientific Review Committee.

Abstracts should include Background and Methods, only:

**Background:**
- Scientific background/rationale for the trial
- Correlative studies of particular interest

**Methods:**
- Trial design and statistical methods, highlighting any novel aspects of the design
- Treatment or intervention planned
- Major eligibility criteria, highlighting unusual aspects
- Clinical trial registry number (required)
- Trial should be open as of August 25, 2021; however, it is not required that the trial be recruiting (current status of “Open but Not Yet Recruiting” is acceptable)
- Current enrollment without providing results or endpoints; for example:
  - Enrollment of next cohort began in August 2021, no DLT were observed in either prior cohort.
  - 10% of planned patients have been enrolled as of August 2021 or initial accrual goal was met; second stage accrual began in August 2021.
  - The trial is continuing as planned; the next data analysis will occur on XX date.

What is not acceptable in a Trials in Progress abstract?
- It is improper and forbidden to include results or preliminary data; any abstracts that include such information will be rejected.
- Proprietary drug names